Vectalys Reprogramming Retroviral Vectors Expressing
Contents
1. 33 5 61 28 70 75 fax 33 5 62 26 12 44 B vectalys vectalys com N S Product Specification Sheet Lecta IVs your gene transfer partner Directions for use Materials Required but Not Provided im B amp B Ww NJ 6 well plates TC grade Cell counter hemocytometer Complete media FBS supplemented Phosphate Buffered Saline PBS Polybrene Hexadimethrine bromide Sigma 107689 10G Directions for use Transduction Protocol for Human Somatic cells The following protocol has been optimized using early passage human foreskin fibroblasts This protocol allowed us to transduce human foreskin fibroblast cells with a transduction efficiency of 100 The following protocol is a working basis and should only be used as a reference to optimize conditions that will enable the generation of iPS cells from other human target cells The pre transduction seeding and cells quantity to be transduced can be modified according to the needs The multiplicity of infection M 0 I the time of viral vectors incubation on cells and the Polybrene concentration are critical points that must strictly be followed Day 0 Cells seeding Seed the cells by plating out from 1x10 to 5x10 cells per well of a 6 well plate according to the cell type you are using Culture medium should be the same as that used to maintain target cells in proliferative state The maximum volume per well of a 6 well plate should be 4ml Incub2. C Keep frozen until use Avoid freeze thaw cycles The use of gloves and disposable lab coats while working with viral derived vectors is strongly recommended This product must only be handled into a biosafety cabinet under BSL 2 controls Retroviral vectors are stable for at least 1 year after receipt when stored at 80 C After first thaw place immediately on ice in any cases please refer to the thawing protocol included into this document The viral vectors are packaged in a working aliquots and only one freeze thaw cycle is required before use In case that more than one freeze thaw cycle are required according to your applications Vectalys recommend to apply a decrease of about 15 in viral vectors titer for each freeze thaw cycles This product is distributed for research use only It is not for use in diagnostic procedures as the safety and efficacy of this product in diagnostic or other clinical uses has not been established The use of retroviral derived vectors implies to follow laboratory biosafety COMPANY Vectalys SAS Canal Biotech Il 3 rue des Satellites 31400 Toulouse T 33 5 61 28 70 75 fax 33 5 62 26 12 44 E vectalys vectalys com N S Product Specification Sheet Lecta IVs your gene transfer partner procedures and practices in agreement with your country regulations SYMBOL CLASSIFICATION A Biorisk class C2L2 Safety precautions The greatest safety risk asso
3. Product Specification Sheet Lectalys your gene transfer partner rectal ys your gene transfer partner Vectalys Reprogramming Retroviral Vectors Expressing Polycistronic Human OSKM for Somatic Cells Reprogramming COMPANY Vectalys SAS T 33 5 61 28 70 75 fax 33 5 62 26 12 44 B vectalys vectalys com Canal Biotech Il 3 rue des Satellites 31400 Toulouse N S Product Specification Sheet Lecta IVs your gene transfer partner Vectalys Reprogramming Retroviral Vectors Human OSKM Catalog Number referring to this User Manual iR OSKM 7 iR OSKM 7P iR OSKM 9 Contents according to your particular Cat Cat iR OSKM 7 10x100ul of Oct4 Sox2 KLF4 and Myc polycistronic retroviral vectors Cat iR OSKM 7P 1x100uI of Oct4 Sox2 KLF4 and Myc polycistronic retroviral vectors Cat iR OSKM 9 5x20ul of Oct4 Sox2 KLF4 and Myc polycistronic retroviral vectors Please refer to the certificate of Analysis CoA for the titer of your particular lot Introduction Induced Pluripotent Stem iPS cells were first obtained by S Yamanaka in 2006 using adult mouse fibroblasts with expression of a select group of transcription factors IPS cells were then obtained from human fibroblasts in 2007 Reprogramming has been achieved in many instances by the co transduction of the four Yamanaka transcription factors Oct4 Sox2 Klf4 and c Myc OSKM in four individual expressio
4. aramachi Higashi iru Kojinguchi dori Kamigyo ku Kyoto 602 0854 JAPAN to the attention of ATTN Vice President License for such use and then shall negotiate for a license from iPS Academia Japan Inc to use the LICENSED PRODUCTS iPSCs generated by use of the LICENSED PRODUCT or derivatives with IPS Academia Japan Inc and agree to take a required license 4 END USER shall not transfer sell or supply any LICENSED PRODUCTS or iPSCs generated by use of the LICENSED PRODUCT or derivatives thereof to any third parties 5 END USER shall not use the LICENSED PRODUCTS or iPSCs generated by use of the LICENSED PRODUCT or derivatives thereof for application and use for human animal therapeutic diagnostic and or prophylactic purposes 6 No other right express or implied is conveyed by the sale of the LICENSED PRODUCTS or the rendering of the LICENSED SERVICES COMPANY Vectalys SAS Canal Biotech Il 3 rue des Satellites 31400 Toulouse T 33 5 61 28 70 75 fax 33 5 62 26 12 44 B vectalys vectalys com
5. ate overnight in a 37 C 5 CO incubator A control well must be set aside for counting the number of cells on the day of transduction Day1 Transduction A Count the number of cells in your control well of the 6 well plate The control well is used to settle the right viral vectors quantity needed to achieve a target M O I and to keep constant the M O I from an experiment to another B Using the following equation determine the right volume of viral vectors required to achieve an adviced M 0 I of 5 Please pay attention to the lot titer as it may vary by lot Number of cells seeded Viral vectors volume required ul _ x M O I x 1000 Viral Vectors Titer TU ml C Thaw the requisite amount of rRV OSKM retroviral vectors according to the thawing protocol mentioned above The viral supernatant has to be homogenized by pipeting up and down and not by inverting upside down the vial D Prepare the transduction mix by adding the required volume of thawed viral particles to the complete media previously supplemented by 20ul of Polybrene 800pg ml The final volume should be 4ml maximum for a transduction in a 6 well plate E Discard the medium from each well and replace it by adding the transduction mix on the cells be careful to apply the transduction mix on well edges to avoid any cell disruption Gently rock the plate from side to side to mix the viral vectors onto the target cells COMPANY Vecta
6. ciated with viral delivery systems comes from the potential generation of recombinant viruses that are capable of autonomous replication during the packaging process The Vectalys reprogramming viral vectors platform eliminates these hazards by combining a disabled viral genome with a unique manufacturing process Also gene functions that facilitate the enclosing of the silencing sequence in a viral capsid e g Gag Pol Env are distributed into multiple helper plasmids which do not contain significant regions of homology during packaging This method further minimizes the probability of recombination events that might otherwise generate viruses capable of autonomous replication With these safety measures in place the Vectalys reprogramming retroviral particles can be employed in standard Biosafety Level 2 tissue culture facilities and should be treated with the same level of caution as with any other potentially infectious agent Also please note that the c Myc and KIf4 proteins are reported to demonstrate oncogenic properties Quality controls The several controls applied to the Vectalys Reprogramming Retroviral Vectors are of different types the viral vectors are tittered in efficient transduction units Viral integration copy number was quantified by transduction of mammalian cells followed by qPCR of the genomic DNA the viral vectors are as well tittered in physical particles by RT qPCR of viral RNA the specific activities according t
7. ean any activity by an END USER including at least one of following activities i use of the LICENSED PRODUCTS or components of vectors or iPSCs generated by use of the LICENSED PRODUCT or derivatives thereof for development or manufacture of related products including but not limited to culture medium and equipment ii use of the LICENSED PRODUCTS or components of vectors or iPSCs generated by use of the LICENSED PRODUCT or derivatives thereof to provide a service information or data to a third party and COMPANY Vectalys SAS L Canal Biotech Il 3 rue des Satellites 31400 Toulouse T 33 5 61 28 70 75 fax 33 5 62 26 12 44 B vectalys vectalys com N Product Specification Sheet Lecta IVs your gene transfer partner iii use of the LICENSED PRODUCTS or components of vectors or iPSCs generated by use of the LICENSED PRODUCT or derivatives thereof for screening compounds antibodies proteins peptides and the other as potential pharmaceutical compounds For the avoidance of doubts any type of joint development between non commercial organization and commercial organization is considered as an internal use for Commercial Purposes 3 If END USER wishes to use the LICENSED PRODUCTS or iPSCs generated by use of the LICENSED PRODUCT or derivatives thereof in the END USER FIELD OF USE for Commercial Purpose END USER notifies IPS Academia Japan Inc Kameya cho Kaw
8. lys SAS Canal Biotech II 3 rue des Satellites 31400 Toulouse T 33 5 61 28 70 75 fax 33 5 62 26 12 44 B vectalys vectalys com N S Product Specification Sheet vecta IVs your gene transfer partner F Incubate the plate 5h in a 37 C 5 CO incubator G After 5 hours incubation discard the transduction mix and wash the cells once with 3ml 1x PBS per well Then discard the PBS and replace it by 4ml of complete media If necessary perform a second transduction by repeating the steps described above A second transduction must not be performed before 48h after the first transduction References 1 Rashid S T Corbineau S Hannan N Marciniak S J Miranda E Alexander G Huang Doran Griffin J Anrlund Richter L Skepper J Semple R Weber A Lomas D A Vallier L Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells J Clin Invest 2010 120 9 3127 3136 2 Lapillonne H Kobari L Mazurier C Tropel P Giarratana M C Zanella Cleon Kiger L Wattenhofer Donze M Puccio H Hebert N Francina A Andreu G Viville S and Douay L Red blood cells generation from human induced pluripotent stem cells perspectives for transfusion medicine Haematologica 2010 95 10 1651 1659 3 Banito A Rashid ST Acosta JC Li S Pereira CF Geti Pinho S Silva JC Azuara V Walsh M Vallier L Gil J Senescence impairs successful reprogramming to pluripotent ste
9. m cells Genes Dev 2009 23 2134 2139 4 Vallier L Touboul T Brown S Cho C Bilican B Alexander M Cedervall J Chandran S Ahrlund Richter L Weber A Pedersen R A Signaling pathways controlling pluripotency and early cell fate decisions of human induced pluripotent stem cells Stem cells 2009 27 11 2655 2666 Notice to purchaser Purchaser represents and warrants that it will use the Vectalys Reprogramming Retroviral Vectors Human OSKM purely for research purposes not for diagnostic use not for resale and not for use in humans or veterinary applications Vectalys will not be held responsible for patent infringement or other violations that may occur with the use of our products Purchaser must determine the suitability of the product s for their particular use Additional terms and conditions may apply End user notice 1 END USER shall not use the LICENSED PRODUCTS iPSCs generated by use of the LICENSED PRODUCT or derivatives thereof for uses other than for END USER s internal research use in the END USER FIELD OF USE 2 END USER FIELD OF USE means noncommercial internal research use only END USER FIELD OF USE excludes research involving application and use of LICENSED PRODUCTS IPSCs generated by use of the LICENSED PRODUCT or derivatives thereof for human animal therapeutic diagnostic and or prophylactic purposes END USER FIELD OF USE also excludes research for Commercial Purpose Commercial Purpose shall m
10. n vectors Successful dedifferentiation requires that a sufficient number of each viral vector deliver the four factors simultaneously to the same cell In many ways iPS cells are similar to embryonic stem ES cells but iPS cells exhibit an undeniable ethical advantage compared to ES cells Vectalys provides highly purified amp concentrated polycistronic retroviral vectors carrying all four expression factors separated by self cleaving 2A peptide sequences Thereby such a single polycistronic cassette enables e the whole set of factors to be integrated into the same integration site e the decrease of the M O I and therefore the viral charge applied to the cells during the transduction allowing better quality iPS cells and safer downstream reprogramming process for disease model and clinical therapies Product Description The Vectalys Reprogramming Retroviral Vectors Human OSKM includes hOct4 hSox2 hKLF4 and hcMyc as prepackaged retroviral particles for reprogramming human somatic cells The high purification level of those retroviral particles allows to transduce primary cells and immortalized cell lines without inducing any toxicity effects to the cells and thus even at high multiplicity of infection M 0 I The expression of these four factors has been shown to direct a variety of differentiated cells into induced pluripotent stem iPS cells with embryonic stem ES cell like properties Handling and Storage Store at 80
11. o DNA and proteins impurities are measured The residual DNA and total proteins are quantified using commercial kits the potential generation of replication competent viruses is tested according to an RCR assay These controls are performed since Vectalys demonstrated the negative impact of residuals DNA and Proteins impurities on cellular toxicity after transduction Transcription factor protein expression was verified by immunocytochemistry analysis of transduced mammalian cells Reprogramming was verified by transduction of human fibroblasts generation of iPS cell colonies and subsequent colony characterization by immunocytochemistry Tested to be negative for Mycoplasma sp by luminometry Directions for use thawing protocol When applicable the vectors should be taken out of the freezer 80 C at the last moment Once thawed the vectors should be used for transduction as soon as possible to avoid degradation In any case it is essential avoiding thermal shock to the cells and vectors If the vectors should be diluted in medium use a medium at room temperature to minimize the heat shock experienced by the vectors and the cells Just before the transduction take out the tubes of viral supernatant of the 80 C freezer and thaw them on ice at 4 C 5 min before transduction take out the tubes of the ice and allow to warm up at room temperature COMPANY Vectalys SAS Canal Biotech Il 3 rue des Satellites 31400 Toulouse T
Download Pdf Manuals
Related Search